A Phase 1 interventional study of 0.5% Ivermectin Cream in Head Lice, sponsored by Topaz Pharmaceuticals Inc. Completed at 5 sites in United States. Open to participants aged 6 Months to 3 Years. Per ClinicalTrials.gov, last updated 2012-04-25.
Sponsored by Topaz Pharmaceuticals Inc · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the bioavailability of 0.5% ivermectin cream in a pediatric population aged 6 months to 3 years.
Topaz Pharmaceuticals Inc is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject's caregiver must agree to comply with the following study restrictions:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: 0.5% Ivermectin Cream
Topical 0.5% ivermectin cream applied to scalp and hair on day 1
Mean Plasma Concentration of Ivermectin in Samples Collected Before Application and at Specified Post-Application Time Points
Plasma concentrations of ivermectin were measured by validated and appropriate bioanalytical instruments and methods with a sensitivity of 0.05 ng/mL before application and on Day 1 (0.5, 1, and 6 hours), Day 2 (24 hours post-application), Day 8 (7 days post-application), and Day 15 (14 days post-application).
Time frame: Before; 0.5, 1, 6, 24 hours and Up to 14 days post-application
Summary of Pharmacokinetic Parameters Following Ivermectin Application.
Plasma concentrations of ivermectin were measured by validated and appropriate bioanalytical instruments and methods before application and on Day 1 (0.5, 1, and 6 hours post-application), Day 2 (24 hours post-application), Day 8 (7 days post-application), and Day 15 (14 days post-application).
Time frame: Before; 0.5, 1, 6, 24 hours, Day 8 and Day 15 post-application
Summary of Pharmacokinetic Parameter (Mean Concentration) Following Ivermectin Application.
Plasma concentrations of ivermectin were measured by validated and appropriate bioanalytical instruments and methods before application and on Day 1 (0.5, 1, and 6 hours post-application), Day 2 (24 hours post-application), Day 8 (7 days post-application), and Day 15 (14 days post-application).
Time frame: Before; 0.5, 1, 6, 24 hours, Day 8 and Day 15 post-application
Summary of Pharmacokinetic Parameter (Time of Observed Maximum Plasma Concentration) Following Ivermectin Application.
Plasma concentrations of ivermectin were measured by validated and appropriate bioanalytical instruments and methods before application and on Day 1 (0.5, 1, and 6 hours post-application), Day 2 (24 hours post-application), Day 8 (7 days post-application), and Day 15 (14 days post-application).
Time frame: Before; 0.5, 1, 6, 24 hours, Day 8 and Day 15 post-application
Number of Participants Reporting Adverse Events Following Ivermectin Treatment
Adverse events were assessed at each visit and during the follow up phone call on Day 28.
Time frame: Day 1 up Day 28 post-application
Percentage of Participants Who Were Lice-Free by Visit Post-treatment With Ivermectin.
Eradication of live lice was assessed by visual examination of the scalp and hair.
Time frame: Day 2, Day 8 and Day 15 post-application
Percentage of Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 8 and Day 15 Post-treatment With Ivermectin.
Eradication of live lice was assessed by visual examination of the scalp and hair before and following application of Ivermectin.
Time frame: Day 2, Day 8 and Day 15 post-application
Liver Function Test Results at Before (Day 1) and Following Ivermectin Application on Days 2, 8, and 15 Post-application
Liver function tests (Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, and Lactate Dehydrogenase) were performed before Ivermectin application on Day 1 (baseline) and on Days 2, 8, and 15 after application.
Time frame: Day 1, Day 2, Day 8 and Day 15 post-application
Liver Function Test Results at Before (Baseline) and Following Ivermectin Application on Days 2, 8, and 15 Post-application
Liver function test (total bilirubin) was performed before treatment Day 1 (baseline) and following Ivermectin application on Days 2, 8, and 15 Post-application, respectively.
Time frame: Day 1, Day 2, Day 8 and Day 15 post-application
Participants were enrolled and treated from 22 September 2009 to 18 November 2009 at 3 US clinical centers.
| Milestone | 0.5% Ivermectin |
|---|---|
| Started | 30 |
| Completed | 27 |
| Not completed | 3 |
| Withdrew: Lost to follow-up | 3 |
Plasma concentrations of ivermectin were measured by validated and appropriate bioanalytical instruments and methods with a sensitivity of 0.05 ng/mL before application and on Day 1 (0.5, 1, and 6 hours), Day 2 (24 hours post-application), Day 8 (7 days post-application), and Day 15 (14 days post-application).
| ng/mL | 0.5% Ivermectin |
|---|---|
| 0 Hour (N = 20) | 0.00000 ± 0.00000 |
| 0.5 Hour (N = 19) | 0.02528 ± 0.11018 |
| 1 Hour (N = 19) | 0.08192 ± 0.22695 |
| 6 Hours (N = 19) | 0.20075 ± 0.20456 |
| 24 Hours (N = 18) | 0.16325 ± 0.08983 |
| 168 Hours (N = 2) | 0.05767 ± NA |
Plasma concentrations of ivermectin were measured by validated and appropriate bioanalytical instruments and methods before application and on Day 1 (0.5, 1, and 6 hours post-application), Day 2 (24 hours post-application), Day 8 (7 days post-application), and Day 15 (14 days post-application).
| ng/h/mL | 0.5% Ivermectin |
|---|---|
| Time Averaged Plasma Concentration | 0.08708 ± 0.11102 |
| Area Under Plasma Concentration Last | 6.701 ± 11.23 |
| Area Under Plasma Concentration 0 to 24 | 3.972 ± 3.5142 |
Adverse events were assessed at each visit and during the follow up phone call on Day 28.
| Participants | 0.5% Ivermectin |
|---|---|
| Diarrhea | 1 |
| Severe Diarrhea | 0 |
| Vomiting | 1 |
| Severe Vomiting | 0 |
| Gastroenteritis | 1 |
| Severe Gastroenteritis | 0 |
| Nasopharyngitis | 2 |
| Severe Nasopharyngitis | 0 |
| Upper Respiratory Tract Infection | 2 |
| Severe Upper Respiratory Tract Infection | 0 |
| Alanine Aminotransferase Increased | 2 |
| Severe Alanine Aminotransferase Increased | 0 |
| Aspartate Aminotransferase Increased | 1 |
| Severe Aspartate Aminotransferase Increased | 0 |
| Dehydration | 1 |
| Severe Dehydration | 0 |
| Dermatitis Diaper | 1 |
| Severe Dermatitis Diaper | 0 |
| Erythema | 5 |
| Severe Erythema | 0 |
| Pruritus | 1 |
| Severe Pruritus | 0 |
Eradication of live lice was assessed by visual examination of the scalp and hair.
| Percent of Participants | 0.5% Ivermectin |
|---|---|
| Day 2 (N = 30) | 97 |
| Day 8 (N = 29) | 90 |
| Day 15 (N = 28) | 89 |
Eradication of live lice was assessed by visual examination of the scalp and hair before and following application of Ivermectin.
| Percent of Participants | 0.5% Ivermectin |
|---|---|
| Eradication by Day 2 (N = 30) | 97 |
| Eradication Maintained Through Day 8 and 15 (N=29) | 86 |
Liver function tests (Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, and Lactate Dehydrogenase) were performed before Ivermectin application on Day 1 (baseline) and on Days 2, 8, and 15 after application.
| U/L | 0.5% Ivermectin |
|---|---|
| Alkaline Phosphatase - Day 1 | 257.9 ± 59.5 |
| Alkaline Phosphatase Day 2 | 258.0 ± 58.4 |
| Alkaline Phosphatase Change from Day 1 to 2 | 4.2 ± 16.5 |
| Alkaline Phosphatase Day 8 | 259.1 ± 51.0 |
| Alkaline Phosphatase Change from Day 1 to 8 | -2.2 ± 28.4 |
| Alkaline Phosphatase Day 15 | 258.3 ± 52.6 |
| Alkaline Phosphatase Change from Day 1 to 15 | -2.9 ± 32.3 |
| Alanine Aminotransferase Day 1 | 25.0 ± 20.5 |
| Alanine Aminotransferase Day 2 | 25.7 ± 20.9 |
| Alanine Aminotransferase Change from Day 1 to 2 | 0.2 ± 20.9 |
| Alanine Aminotransferase Day 8 | 25.1 ± 22.1 |
| Alanine Aminotransferase Change from Day 1 to 8 | -0.2 ± 5.3 |
| Alanine Aminotransferase Day 15 | 24.1 ± 15.5 |
| Alanine Aminotransferase Change from Day 1 to 15 | -1.1 ± 8.9 |
| Aspartate Aminotransferase Day 1 | 42.6 ± 15.4 |
| Aspartate Aminotransferase Day 2 | 41.1 ± 11.5 |
| Aspartate Aminotransferase Change from Day 1 to 2 | -2.0 ± 15.4 |
| Aspartate Aminotransferase Day 8 | 40.3 ± 14.0 |
| Aspartate Aminotransferase Change from Day 1 to 8 | -2.3 ± 6.8 |
| Aspartate Aminotransferase Day 15 | 39.5 ± 9.6 |
| Aspartate Aminotransferase Change from Day 1 to 15 | -2.7 ± 10.2 |
| Lactate Dehydrogenase Day 1 | 308.0 ± 87.5 |
| Lactate Dehydrogenase Change Day 2 | 295.2 ± 35.8 |
| Lactate Dehydrogenase Change from Day 1 to 2 | -16.8 ± 95.1 |
| Lactate Dehydrogenase Day 8 | 295.1 ± 54.0 |
| Lactate Dehydrogenase Change from Day 1 to 8 | -10.7 ± 80.2 |
| Lactate Dehydrogenase 15 | 294.5 ± 61.3 |
| Lactate Dehydrogenase Change from Day 1 to 15 | -9.2 ± 69.0 |
Liver function test (total bilirubin) was performed before treatment Day 1 (baseline) and following Ivermectin application on Days 2, 8, and 15 Post-application, respectively.
| mg/dL | 0.5% Ivermectin |
|---|---|
| Total Bilirubin - Day 1 | 0.3 ± 0.3 |
| Total Bilirubin Day 2 | 0.3 ± 0.3 |
| Total Bilirubin Change from Day 1 to 2 | -0.0 ± 0.1 |
| Total Bilirubin Day 8 | 0.3 ± 0.3 |
| Total Bilirubin Change from Day 1 to 8 | -0.0 ± 0.1 |
| Total Bilirubin Day 15 | 0.3 ± 0.3 |
| Total Bilirubin Change from Day 1 to 15 | -0.1 ± 0.2 |
Plasma concentrations of ivermectin were measured by validated and appropriate bioanalytical instruments and methods before application and on Day 1 (0.5, 1, and 6 hours post-application), Day 2 (24 hours post-application), Day 8 (7 days post-application), and Day 15 (14 days post-application).
| ng/mL | 0.5% Ivermectin |
|---|---|
| Summary of Pharmacokinetic Parameter (Mean Concentration) Following Ivermectin Application. | 0.241 ± 0.23372 |
Plasma concentrations of ivermectin were measured by validated and appropriate bioanalytical instruments and methods before application and on Day 1 (0.5, 1, and 6 hours post-application), Day 2 (24 hours post-application), Day 8 (7 days post-application), and Day 15 (14 days post-application).
| hour | 0.5% Ivermectin |
|---|---|
| Summary of Pharmacokinetic Parameter (Time of Observed Maximum Plasma Concentration) Following Ivermectin Application. | 15.9 ± 10 |
Collected over Adverse event data were collected from the day of application (Day 1) through Day 28 post-application. Non-serious events are listed at a 5.00% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.5% Ivermectin | — | 1/30 (3.3%) | 11/30 (36.7%) |
| Event | 0.5% Ivermectin |
|---|---|
| GastroenteritisInfections and infestations | 1/30 |
| DehydrationMetabolism and nutrition disorders | 1/30 |
| Dermatitis DiaperSkin and subcutaneous tissue disorders | 1/30 |
| Event | 0.5% Ivermectin |
|---|---|
| ErythemaSkin and subcutaneous tissue disorders | 5/30 |
| NasopharyngitisInfections and infestations | 2/30 |
| Upper Respiratory Tract InfectionInfections and infestations | 2/30 |
| Alanine Aminotransferase IncreasedInvestigations | 2/30 |
| Age, Categorical(Participants) | 0.5% Ivermectin |
|---|---|
| <=18 years | 30 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Age Continuous(Months) | 0.5% Ivermectin |
|---|---|
| Mean | 25.8 ± 11.0 |
| Sex: Female, Male(Participants) | 0.5% Ivermectin |
|---|---|
| Female | 23 |
| Male | 7 |
| Region of Enrollment(Participants) | 0.5% Ivermectin |
|---|---|
| United States | 30 |
The record gives a start of Sep 2009, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivermectin
Topaz Pharmaceuticals Inc